GlassScriptPhysician profile
Jennifer D Williams
NPI 1063452654
$9,581.50
in general payments reported to CMS, 2019-2025
47 companies · $1,135 in 2025
The $1,135 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $922 · 2020: $1,413 · 2021: $1,597 · 2022: $1,566 · 2023: $1,710 · 2024: $1,239 · 2025: $1,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,858 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,858.04 |
| Education | $225.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,490.58 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,240.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $848.37 | 2019-2024 | |
| Lilly USA, LLC | $672.56 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $627.20 | 2019-2024 | |
| Astellas Pharma US INC | $587.46 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $411.20 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.74 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $300.46 | 2019-2023 | Trintellix |
| Esperion Therapeutics, INC. | $284.97 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $233.33 | 2022-2025 | |
| Currax Pharmaceuticals LLC | $198.04 | 2020-2025 | Contrave, Nexlizet, Nexletol |
| Ironshore Pharmaceuticals INC. | $184.80 | 2019-2023 | Jornay Pm |
| Merck Sharp & Dohme LLC | $173.75 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $158.75 | 2019-2023 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.